Phacilitate Advanced Therapies 2024
With the recent approval of two new gene therapies for sickle cell disease, the consistent development of cell and gene therapies are in the spotlight. Further successful clinical trials will be needed for the potential of these therapies to be realized in other conditions. With over 2,000 clinical programs globally and an anticipated growth rate of 25% in the next five years, the industry faces multifaceted challenges such as evolving stakeholder requirements, complex logistics for study planning, and mandated long-term patient follow-up.
Fireside Chat
Designing Optimal Clinical Trials and Clinical Operations for Advanced Therapies
January 18 | 10:00 a.m. EST
Abhi Gupta, Senior Vice President & Head of Cell and Gene Therapy, Syneos Health
Abhi Gupta is Senior Vice President, Head of Cell and Gene Therapy, at Syneos Health in April 2023. In his role, he drives the development and operationalization of strategic clinical and commercial solutions that accelerate the impact of life-changing genetic medicines for Syneos Health customers and their patients. Prior to Syneos Health, Abhi held various leadership and scientific positions at Pfizer, Regeneron, Citigroup, BMS, and Johnson & Johnson. He is passionate about improving the real-world life experiences of genetic medicine patients and their families and overcoming the pressing challenges of cell and gene therapy research.
Key Topics:
- Why do we need an end-to-end drug development model that incorporates commercial view into designing clinical trials for genetic medicines?
- What are some immediate opportunities for early-stage companies to de-risk their clinical model and ensure future success?
- What have been the key lessons learned in developing and commercializing cell and gene therapies?
Check out more Cell & Gene Therapy Thought Leadership on Insights Hub
Additional Resources:
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
Exploring an Expedited Regulatory Pathway for Cell and Gene Therapies
Cell and Gene Therapy Sponsors Must Overcome Unique Hurdles to Realize Promise to Patients
Strategies for Small Biotech in the Development of Cell Therapy Trials
